Company* (Country; Symbol) |
Company* (Country; Symbol) |
Type/Product Area |
Terms/Details (Date) |
| |||
Asuragen Inc.* |
Millennium Pharmaceuticals Inc. (MLNM) |
Agreement for Asuragen to provide laboratory testing to assist in gene expression studies being conducted by Millennium |
Terms were not disclosed (5/29) |
BioSeek Inc.* |
Amylin Pharmaceuticals Inc. (AMLN) |
Partnership focused on the potential of peptides against inflammatory disease |
Deal includes a $10M investment for BioSeek (5/22) |
BG Medicine Inc.* indicator of congestive heart failure |
ACS Biomarker BV* (the Netherlands) |
Agreement granting BG rights to develop and commercialize a biomarker- based molecular diagnostic test as a prognostic |
BG has an exclusive, worldwide sublicense from ACS to rights owned by the University of Maastricht and the Academic Hospital Maastricht relating to galectin-3 and another blood-plasma biomarker (5/23) |
Crucell NV (the Netherlands; CRXL) and Royal Pharma DSM NV (the Netherlands) |
Sartorius Biotech GmbH (Germany; FSE:SRT) |
Nonexclusive PER.C6 research licensing deal |
Sartorius will use the technology to evaluate monoclonal antibodies produced using PER.C6 cells for calibrating and testing equipment products useful in the manufacture and/or purification of recombinant monoclonal antibodies (6/5) |
Coley Pharmaceutical Group Inc. (COLY) |
3M Co. (NYSE:MMM) |
Agreement to acquire TLR7 and TLR8 programs from 3M |
Coley will make four cash payments of $5M each over the next three years; 3M also may receive regulatory milestone payments and single-digit royalties (6/12) |
Danube Pharmaceuticals Inc.* |
Aptuit Inc.* |
Deal in which Aptuit will provide Danube with a full range of drug development services |
The agreement will employ five of Aptuit's facilities to develop and manufacture Danube's investigational compound to support upcoming Phase II studies (6/4) |
Evotec AG (Germany; FSE:EVT) Pharmaceuticals Pte. Ltd.*) |
Combinature Biopharm (a unit of MerLion magnetic resonance screening as well as access to the SAR-by- NMR intellectual property |
Agreement under which Evotec acquired equipment and expertise in nuclear |
Evotec plans to integrate the technologies with its high-throughput, high-concentration biochemical assay approach (6/13) |
Exact Sciences Corp. (EXAS) |
NorDiag ASA (Norway; OSLO: NORD) |
Agreement to advance the development and com- mercialization of colorectal cancer screening tech- nologies outside the U.S. and Canada |
Exact extended a nonexclusive license to its DIA technology and related know-how to NorDiag for commercializing such tests in Europe, Japan and Australia; NorDiag will pay a licensing fee and royalties (6/5) |
Favrille Inc. (FVRL) |
Diversa Corp. (DVSA) |
Agreement for Favrille to acquire a series of optimized anti-CD20 monoclonal antibodies from Diversa |
Favrille gains rights to antibodies optimized with Diversa technology, along with the corresponding patents and an exclusive, royalty-free license to selected pending patents for commercialization of the panel (6/12) |
GenomeQuest Inc.* |
ARYx Therapeutics Inc.* |
Agreement to provide its GenomeQuest archive of close to 67M patented sequences to ARYx |
ARYx will use the technology to evaluate new gene sequences (6/5) |
Materia Inc.* |
Eisai Co. Ltd. (Japan; FSE:EII) |
Nonexclusive licensing agreement to Materia's metathesis platform |
Eisai gained rights to discover, develop and patent pharmaceutical compounds and related processes using Materia's catalysts and associated intellectual property (6/20) |
Molecular Insight Pharmaceuticals Inc. (MIPI) |
NeoRx Manufacturing Group Inc. (subsidiary of Poniard Pharmaceuticals Inc.; PARD) |
Purchase agreement to buy a commercial-scale radiopharmaceutical manufacturing facility |
Molecular Insight is acquiring the facility from NeoRx for $3M (5/18) |
Morphotek Inc.* |
CMB Biopharma- ceuticals* (Denmark) |
Agreement for development, manufacturing and regulatory documentation support of MORAb-028, an antibody targeting advanced melanoma and other cancers |
The compound is ready to enter clinical development in 2008 (5/21) |
Neuronascent Inc.* |
Lifeline Cell Technology LLC (unit of International Stem Cell Corp.; OTC BB:ISCO) |
Licensing agreement for certain animal cells |
It covers the exclusive, worldwide rights to market, sell and distribute adult Arctic ground squirrel neural stem cells for research use; Neuronascent is entitled to license fees and royalty payments (5/29) |
Oxford Gene Technology* (UK) |
Aushon BioSystems* |
Agreement for access to OGT's Southern array patents, which cover the manufacture and marketing of oligonucleotide microarrays |
The license will remain valid for the patents' lifetime (6/12) |
Par Pharmaceutical Cos. Inc. (NYSE:PRX) |
Immtech Pharmaceuticals Inc. (AMEX:IMM) |
Exclusive rights agreement in the U.S. to a Phase III drug to treat pneumocystis pneumonia in AIDS patients |
Par is paying Immtech $3M up front; the deal includes up to $29M in milestone payments through FDA approval, up to $115M in milestones based on sales, and royalties on sales; Par gets exclusive rights to DB289, pafuramidine maleate (6/12) |
Peregrine Pharmaceuticals Inc. (PPHM) |
Dios Therapeutics Inc.* |
Collaboration under which Peregrine will provide process development and manufacturing services and know-how to support early clinical development of Dios' humanized monoclonal antibody to treat thyroid-associated ophthalmo- pathy, a severe form of Grave's disease |
Peregrine has the option to convert its development fees into either cash or equity in Dios; it also could receive royalties and Dios would have the option to buy out the royalty obligations for $50M (5/31) |
ProBioGen AG* (Germany) |
Virbac SA (France; PARIS: VIRP) |
Licensing agreement for designer avian cell lines to Virbac |
Virbac will use the cell lines based on duck retina AGE1.cr and somite cells AGE1.cs as the production platform to develop biologicals (5/31) |
ProMetic BioTherapeutics Inc. (unit of ProMetic Life Sciences Inc.; Canada; TSX:PLI) |
Blue Blood Biotech Corp.* (Taiwan) |
Alliance to develop drugs derived from human plasma using ProMetic's manufacturing process |
The partnership initially will target hyper- immune Cytomegalovirus, as well as two other high value therapeutics, with Taiwan and Southeast Asia as the primary markets (7/11) |
Quest Group International Inc. (OTC BB:QSTG) |
Vitae Pharmaceuticals Inc.* |
Licensing agreement for retinoic acid receptor agonists and antagonists, as well as a rexinoid small molecule |
One compound is ready to enter Phase II testing for acute leukemia; another will be evaluated for safety in common cancers; and a third will be developed to reduce the toxicity of chemotherapy (5/18) |
Sciele Pharma Inc. (SCRX) |
Plethora Solutions Holdings plc (UK; LSE:PLE) |
Agreement for exclusive U.S. rights from Plethora to PSD502, which is in Phase II trials for premature ejaculation |
Sciele is purchasing a $7M equity stake in Plethora, which is entitled to milestone payments and royalties; Plethora also will have co-promotion rights for urologists in the U.S. (5/24) |
Synosia Therapeutics* |
Syngenta AG (Switzerland; NYSE:SYT) |
License agreement to develop a potential treatment of Parkinson's disease |
The compound, SYN-118, is approved in the U.S. and Europe for the metabolic disorder hereditary tyrosinemia Type I; Synosia will be responsible for ongoing clinical development and commercialization, while Syngenta is eligible for milestones and royalties (5/22) |
Transgenomic Inc. (OTC BB:TBIO) |
Canadian Food Inspection Agency and Transition Technologies Inc.* |
Collaboration for the development of novel molecular PCR-based assays for the detection of animal materials that have been banned from cattle feed |
The project is a means to verify enforcement of Canada's feed controls (6/14) |
Vegenics Ltd.* |
CoGenesys Inc.* |
Licensing agreement for exclusive worldwide rights to human monoclonal antibodies that target vascular endothelial growth factor-C |
Terms were not disclosed (6/18) |
Notes: | |||
* Private companies are indicated with an asterisk; ** Denotes the date the item ran in BioWorld International. Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market. AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. |